Gosselies, Belgium (PRWEB) June 17, 2013
Euroscreen SA presented ESN314, a potent small-molecule NK3 receptor antagonist, at the Endocrine Society’s Annual Meeting in San Francisco. Euroscreen and collaborating scientists disclosed preclinical pharmacokinetic and efficacy data demonstrating the utility of NK3 antagonists to modulate the Hypothalamic-Pituitary-Gonadal (HPG) axis, a validated therapeutic axis targeted for the treatment of sex hormone disorders.
This study provides the first demonstration that the oral administration of ESN314 decreases the plasma levels of Lutenizing Hormone (LH), but not Follicle-Stimulating Hormone (FSH) in non-rodent models. This selective reduction of plasma LH offers a more refined modulation of the HPG axis than the existing GnRH antagonist therapies.
ESN314 is a representative molecule from the proprietary series discovered at Euroscreen. The lead development candidate issued from this program, ESN364, is on-schedule for first-in-human dosing in Q4, 2013. Euroscreen will develop its lead candidate ESN364 for the treatment of reproductive disorders such as Endometriosis and Polycystic Ovary Syndrome (PCOS).
"Hormone disorder diseases such as Endometriosis, PCOS or Benign Prostate Hyperplasia (BPH) represent a huge market opportunity with a persistent medical need for new products with a superior profile to the existing therapies” said Jean Combalbert, CEO of Euroscreen. “We are the leaders in drug development for this first-in-class approach. Our drug candidate has an excellent preclinical safety and efficacy profile and we look forward to the outcomes of the Clinical Phase I studies in the coming months.”
Euroscreen has a drug development track-record with multiple innovative and proprietary chemical entities targeting G Protein Coupled Receptors (GPCR).
Euroscreen is advancing its orally-available and highly specific lead program ESN364 into clinical trials for women’s diseases such Endometriosis and PCOS. The Company is also actively seeking partners for other pharmaceutical candidates, such as its ESN282 program for the treatment of inflammatory diseases such as Ulcerative Colitis.
Euroscreen is a Belgium-based, private Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including inflammation, neurodegenerative diseases and women’s diseases.
Euroscreen also has a dedicated business providing fee-for-service drug candidate testing (Euroscreen FAST) for biopharmaceutical companies worldwide.
The Company is backed by leading investors, including Vesalius Biocapital, SRIW, Fortis Private Equity, and others.
Further information about the Company and its drug development programs can be found online at http://www.euroscreen.com or by contacting info(at)euroscreen(dot)com.